A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 143

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 143
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 209
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 994
Function: getPubMedXML

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3134
Function: GetPubMedArticleOutput_2016

File: /var/www/html/application/controllers/Detail.php
Line: 574
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 488
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

A Comparison of TearCare and Lipiflow Systems in Reducing Dry Eye Disease Symptoms Associated with Meibomian Gland Disease. | LitMetric

AI Article Synopsis

  • The study aimed to compare the effectiveness of TearCare and LipiFlow systems in alleviating symptoms of dry eye disease (DED) linked to meibomian gland dysfunction (MGD).
  • A total of 235 participants were treated with either TearCare or LipiFlow and monitored for symptom improvement over a month using different questionnaires.
  • Results showed that TearCare significantly outperformed LipiFlow in reducing DED symptoms, especially in patients with more severe gland obstruction.

Article Abstract

Purpose: To compare TearCare and Lipiflow systems in the ability to reduce the symptoms of dry eye disease (DED) associated with meibomian gland dysfunction (MGD).

Methods: In this multicenter, masked, randomized-controlled trial, 235 subjects received a single TearCare treatment (n = 115) or a single LipiFlow treatment (n = 120) and were followed for 1-month post-treatment. DED symptoms were assessed using the Ocular Surface Disease Index (OSDI), Symptom Assessment in Dry Eye (SANDE), and Eye Dryness (ED) questionnaires at baseline and at 1 month. Post-hoc subgroup analysis was conducted on subjects with less severe and more severe gland obstruction determined by baseline meibomian gland secretion score (MGSS).

Results: TearCare system significantly improved total OSDI, SANDE, and ED scores from baseline ( < 0.0001) at 1-month follow-up. Subjects with more severe disease (MGSS <7) achieved statistically greater reduction with TearCare compared to LipiFlow in total OSDI score (30.4 ± 2.53 and 21.9 ± 2.37, respectively, = 0.0160), OSDI Section B score for quality of vision (5.1 ± 0.48 and 3.6 ± 0.45, respectively, = 0.0206), and SANDE frequency score (51.9 ± 3.70 and 41.5 ± 3.45, respectively, = 0.0455).

Conclusion: TearCare provides significant DED symptom relief at 1 month after a single treatment. Outcomes were consistent in OSDI, SANDE, and ED assessments. In subjects with more severe gland dysfunction, TearCare performed significantly better than LipiFlow in improving quality of vision and overall DED symptom frequency determined by OSDI and SANDE.

Clinical Trial Registration Number: NCT03857919.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9440678PMC
http://dx.doi.org/10.2147/OPTH.S368319DOI Listing

Publication Analysis

Top Keywords

dry eye
12
meibomian gland
12
tearcare lipiflow
8
lipiflow systems
8
eye disease
8
associated meibomian
8
subjects severe
8
disease
5
comparison tearcare
4
systems reducing
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!